PEDIATRICS Vol. 40 No. 4 October 1967, pp. 691-693
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DAVIS, S. D.
Right arrow Articles by WEDGWOOD, R. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by DAVIS, S. D.
Right arrow Articles by WEDGWOOD, R. J.

Letters to the Editor

STARKEY D. DAVIS M.D.1 and RALPH J. WEDGWOOD M.D.2

1 Assistant Professor, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98105
2 Professor and Chairman, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98105

Dr. Yerushalmy points out the excess mortality in the isoniazid pupulation in two trials: contacts of new cases and patients in mental hospitals. He failed to mention that the Public Health Service has conducted five other isoniazid prophylaxis trials (Table I). In the six trials listed, excluding the one in institutions, the isoniazid groups had more deaths in three trials, the placebo group had more deaths in two trials, and in one trial the number of deaths in each group was equal.